Trial Profile
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs BR-55 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Bracco Diagnostics
- 08 Aug 2023 Planned End Date changed from 1 Aug 2021 to 31 Mar 2024.
- 08 Aug 2023 Status changed from completed to active, no longer recruiting.
- 28 Feb 2022 Status changed from recruiting to completed.